NKTR Stock: Price, Earnings History and SEC Filings
Nektar Therapeutics (NKTR) last traded at $38.87, down 0.79% on the latest session and down 35.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.23 against an analyst estimate of $-2.06, a beat of 40.3%.
$38.87 -0.79%
1 month-35.81%
52-week high$109.00
52-week low$33.40
Volume600,972
ExchangeNasdaqCM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NKTR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 13, 2026 | $-1.23 | $-2.06 | +40.29% |
| Mar 2026 | May 7, 2026 | $-1.82 | $-1.74 | -4.60% |
| Dec 2025 | Mar 12, 2026 | $-1.78 | $-2.76 | +35.51% |
| Sep 2025 | Nov 6, 2025 | $-1.85 | $-2.85 | +35.09% |
NKTR beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for NKTR
SEC filing data is not available right now. You can search for NKTR on SEC EDGAR.
NKTR news
- Nektar Therapeutics: Focus Returns To The Strengths Of The CompanyOct 30, 2026 · seekingalpha.com
- Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?Oct 29, 2026 · finance.yahoo.com
- Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial MarketsOct 27, 2026 · finance.yahoo.com
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Oct 23, 2026 · finance.yahoo.com
About Nektar Therapeutics
Nektar Therapeutics (NKTR) is a US-listed public company on Nasdaq.